OPRD1

OPRD1 encodes the delta-opioid receptor (DOR), a G protein-coupled receptor whose expression is governed by multiple cis-regulatory and trans-acting controls and whose downstream behavioral output depends on the neuronal cell type in which it is expressed [PMID:39496614, PMID:38585789, PMID:bio_10.1101_2025.11.14.688475]. At the regulatory level, promoter and intronic variants tune transcription through differential transcription factor recruitment: the minor G-allele of the promoter SNP rs569356 enhances nuclear transcription-factor binding and increases transcriptional activity (PMID:20300121), while the intronic variant rs678849 partitions binding between XRCC6 (C allele, lower expression) and hnRNP D0 (T allele, higher expression) (PMID:34407719). In dorsal root ganglion sensory neurons, peripheral nerve injury upregulates the transcriptional repressor REST, which occupies the Oprd1 promoter to repress its transcription; conditional deletion of REST restores Oprd1 expression and attenuates pain hypersensitivity, linking DOR downregulation to nerve-injury pain (PMID:39496614, PMID:38585789). At the circuit level, DOR on parvalbumin interneurons is selectively required for the convulsant and anxiolytic effects of the DOR agonist SNC80 but is dispensable for its pro-locomotive and respiratory effects, demonstrating that distinct DOR-expressing populations segregate the receptor's behavioral consequences [PMID:bio_10.1101_2025.11.14.688475]. The receptor's own signal-transduction biochemistry is not characterized in the available corpus, which is dominated by transcriptional and cell-type-resolved functional studies.

1. 2010 Medium

   Establishing whether a common OPRD1 promoter variant is functional, this work showed that an allele-specific transcription-factor binding event sets expression level — converting a genetic association into a mechanistic regulatory hypothesis.

   Evidence Luciferase reporter assay in HEK293 cells and EMSA with human brain nuclear proteins

   PMID:20300121

   Open questions at the time

   • The specific transcription factor binding the G-allele was not identified
   • Effect not validated at endogenous OPRD1 locus in neurons
2. 2017 Low

   Probing epigenetic control, this study showed that an OPRD1 promoter CpG region is itself transcriptionally active, framing methylation of these sites as a plausible expression switch.

   Evidence Luciferase reporter gene assay of a CpG-containing promoter fragment

   PMID:28253273

   Open questions at the time

   • Single-method reporter assay without methylation-dependent functional test
   • No identification of factors reading the CpG sites
   • Not tested at endogenous locus
3. 2021 Medium

   Extending allele-specific regulation beyond the promoter, this work identified the actual proteins discriminating an intronic variant, showing XRCC6 and hnRNP D0 bind opposing alleles to set differential expression.

   Evidence Luciferase reporter assay in BE(2)C neuroblastoma cells with EMSA/supershift and proteomic identification using neuroblastoma and human medial prefrontal cortex lysates

   PMID:34407719

   Open questions at the time

   • Binding partners identified in vitro but not validated by loss-of-function at the endogenous gene
   • Not independently replicated
   • Functional consequence of XRCC6/hnRNP D0 binding in vivo unestablished
4. 2024 High

   Linking OPRD1 regulation to a disease state, this work showed that nerve injury drives REST-mediated repression of Oprd1 in sensory neurons and that relieving this repression rescues both expression and pain behavior.

   Evidence Conditional Rest knockout in primary sensory neurons with ChIP, qRT-PCR, transcriptomics, and behavioral pain assays in the spared nerve injury model

   PMID:38585789 PMID:39496614

   Open questions at the time

   • Whether restored DOR signaling, rather than other REST targets, mediates the analgesia is not isolated
   • Direct REST binding mapped by ChIP but not at base-pair resolution
5. 2025 Medium

   Resolving why DOR agonists produce mixed therapeutic and adverse effects, this work showed that DOR on parvalbumin interneurons selectively drives convulsant and anxiolytic responses while leaving locomotor and respiratory effects intact, dissecting the receptor's circuit-level functions.

   Evidence Cell-type-specific conditional DOR knockout (Floxed DOR; PV-Cre) with whole-cell electrophysiology and convulsant, locomotor, anxiety, and respiratory behavioral assays (preprint)

   PMID:bio_10.1101_2025.11.14.688475

   Open questions at the time

   • Preprint, not yet peer-reviewed
   • Cell types mediating pro-locomotive and respiratory effects not identified
   • Downstream signaling from PV-neuron DOR not defined

• The signal-transduction biochemistry of the delta-opioid receptor itself — its G-protein coupling, effector engagement, and ligand-binding determinants — remains uncharacterized in this corpus, which focuses on transcriptional regulation and cell-type-specific behavior.
• No biochemical or structural characterization of DOR signaling in the timeline
• No agonist/antagonist pharmacology beyond SNC80 behavioral readouts
• No direct physical receptor partners defined